Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

50.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability
Sanofi reports show significant improvements in hidradenitis suppurativa symptoms, with higher response rates and reduced lesions. 
Via Benzinga
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows. 
Via Benzinga
Topics Government
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More
Via Stocktwits
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification
Via Stocktwits
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Roblox To Rally Around 34%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Why Nektar Therapeutics Rippled Higher This Week
The company's competitive positioning might be stronger now, after disappointing results from a key rival. 
Via The Motley Fool
Topics Intellectual Property
What's Going On With Nektar Therapeutics Stock On Thursday?
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results. 
Via Benzinga
Why Is Sanofi Stock Falling Thursday?
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential. 
Via Benzinga
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise. 
Via Benzinga
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
Can anything beat out Dupixent's "compelling bar" for effectiveness? 
Via Investor's Business Daily
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
This Monster Beverage Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
 
Via Benzinga
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales
Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi. 
Via Benzinga
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca
Via Stocktwits
What's Driving the Market Sentiment Around Sanofi?
 
Via Benzinga
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts
These biotech businesses look compelling for very different reasons. 
Via The Motley Fool
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients
FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes. 
Via Benzinga
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals. 
Via Benzinga
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount
Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential contrarian discount. 
Via Benzinga
Topics Earnings
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward. 
Via Benzinga
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save. 
Via The Motley Fool
Topics Artificial Intelligence Retirement
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.